CELEX: 62007TJ0493
Language: en
Date: 2009-09-23
Title: Judgment of the Court of First Instance (Seventh Chamber) of 23 September 2009. # GlaxoSmithkline SpA and Others v Office for Harmonisation in the Internal Market (Trade Marks and Designs) (OHIM). # Community trade mark - Invalidity proceedings - Community word mark FAMOXIN - Earlier national word marks LANOXIN - Relative ground for refusal - No likelihood of confusion - Article 8(1)(b) and Article 52(1)(a) of Regulation (EC) No 40/94 (now Article 8(1)(b) and Article 53(1)(a) of Regulation (EC) No 207/2009) - Proof of use - Article 56(2) and (3) of Regulation No 40/94 (now Article 57(2) and (3) of Regulation No 207/2009). # Cases T-493/07, T-26/08 and T-27/08.

Judgment of the Court of First Instance (Seventh Chamber) of 23 September 2009 – GlaxoSmithkline and Others v OHIM – Serono
            Genetics Institute (FAMOXIN)
      (Cases T-493/07, T-26/08 and T-27/08)
      Community trade mark – Invalidity proceedings – Community word mark FAMOXIN – Earlier national word marks LANOXIN – Relative ground for refusal – No likelihood of confusion – Article 8(1)(b) and Article 52(1)(a) of Regulation (EC) No 40/94 (now Article 8(1)(b) and Article 53(1)(a) of Regulation
         (EC) No 207/2009) – Proof of use – Article 56(2) and (3) of Regulation No 40/94 (now Article 57(2) and (3) of Regulation No 207/2009
      
      Community trade mark – Surrender, revocation and invalidity – Relative grounds of invalidity – Registration contrary to Article 8(1)(b) of Regulation No 40/94 (Council Regulation No 40/94, Art. 52(1)(a)) (see paras 50-57,
         73-76)
      
      Re:
      
         Three actions brought against the decisions of the First Board of Appeal of the Office for Harmonisation in the Internal Market
                  (Trade Marks and Designs) of 14 September 2007 (Case R 8/2007-1), 20 November 2007 (Case R 10/2007-1) and 19 November 2007
                  (Case R 9/2007-1), relating to cancellation proceedings between, on the one hand, GlaxoSmithkline SpA, Laboratórios Wellcome
                  De Portugal L
               
               da
                and The Wellcome Foundation Ltd, and, on the other, Serono Genetics Institute SA.
            Information relating to the case
      
               Registered Community trade mark subject of the application for a declaration of invalidity:
            
            
               Community word mark FAMOXIN for goods and services in Class 5 – Application No 2491298
            
         
               Proprietor of the Community trade mark:
            
            
               Serono Genetics Institute SA
            
         
               Party requesting the declaration of invalidity of the Community trade mark:
            
            
               GlaxoSmithkline SpA ; Laboratórios Wellcome de Portugal, Lda ; and The Wellcome Foundation Ltd
               
            
         
               Trade mark right of the party requesting the declaration of invalidity:
            
            
               National word mark LANOXIN for goods in Class 5
            
         
               Decision of the Cancellation Division:
            
            
               Applications dismissed
            
         
               Decision of the Board of Appeal:
            
            
               Appeals dismissed
            
         Operative part
      The Court:
      
         
                  1.
               
               
                  
               
               
                  	Joins Cases T-493/07, T-26/08 and T-27/08 for the purposes of the present judgment;
               
            
         
                  2.
               
               
                  
               
               
                  	Dismisses the actions;
               
            
         
                  3.
               
               
                  
               
               
                  	Orders GlaxoSmithKline SpA, Laboratórios Wellcome de Portugal, Lda and The Wellcome Foundation Ltd to pay the costs.